Arid1a Loss Enhances Disease Progression in a Murine Model of Osteosarcoma

Author:

Fatema Kaniz1ORCID,Wang Yanliang234,Pavek Adriene1,Larson Zachary1,Nartker Christopher1,Plyler Shawn1,Jeppesen Amanda1,Mehling Breanna1,Capecchi Mario R.5,Jones Kevin B.234,Barrott Jared J.123467ORCID

Affiliation:

1. Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Idaho State University, Pocatello, ID 83209, USA

2. Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City, UT 84132, USA

3. Department of Orthopaedics, University of Utah School of Medicine, Salt Lake City, UT 84132, USA

4. Huntsman Cancer Institute, Salt Lake City, UT 84112, USA

5. Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, UT 84132, USA

6. Department of Cell Biology and Physiology, Brigham Young University, Provo, UT 84602, USA

7. Simmons Center for Cancer Research, Provo, UT 84602, USA

Abstract

Osteosarcoma is an aggressive bone malignancy, molecularly characterized by acquired genome complexity and frequent loss of TP53 and RB1. Obtaining a molecular understanding of the initiating mutations of osteosarcomagenesis has been challenged by the difficulty of parsing between passenger and driver mutations in genes. Here, a forward genetic screen in a genetic mouse model of osteosarcomagenesis initiated by Trp53 and Rb1 conditional loss in pre-osteoblasts identified that Arid1a loss contributes to OS progression. Arid1a is a member of the canonical BAF (SWI/SNF) complex and a known tumor suppressor gene in other cancers. We hypothesized that the loss of Arid1a increases the rate of tumor progression and metastasis. Phenotypic evaluation upon in vitro and in vivo deletion of Arid1a validated this hypothesis. Gene expression and pathway analysis revealed a correlation between Arid1a loss and genomic instability, and the subsequent dysregulation of genes involved in DNA DSB or SSB repair pathways. The most significant of these transcriptional changes was a concomitant decrease in DCLRE1C. Our findings suggest that Arid1a plays a role in genomic instability in aggressive osteosarcoma and a better understanding of this correlation can help with clinical prognoses and personalized patient care.

Funder

the INBRE PROGRAM, NIH

Almac Diagnostics Partnership Award

Idaho State Career Path Internships

the L.B. and Olive S. Young Presidential Chair for Cancer Research

the Huntsman Cancer Foundation

the University of Utah Department of Orthopaedics

the National Cancer Institute

National Institutes of Health

Publisher

MDPI AG

Reference79 articles.

1. Survival from adolescent cancer;Desandes;Cancer Treat Rev.,2007

2. Heymann, D. (2021). Bone Cancer: Bone Sarcomas and Bone Metastases—From Bench to Bedside, Academic Press. [3rd ed.].

3. Sarcoma treatment in the era of molecular medicine;Alonso;EMBO Mol. Med.,2020

4. Pilavaki, P., Gahanbani Ardakani, A., Gikas, P., and Constantinidou, A. (2023). Osteosarcoma: Current Concepts and Evolutions in Management Principles. J. Clin. Med. Res., 12.

5. Review of Osteosarcoma and Current Management;Durfee;Rheumatol. Ther.,2016

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3